Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eldon Smith | M | 84 |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 11 years |
| Christopher Waddick | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 12 years |
| Daniel Johnson | M | 79 |
University of London
| 6 years |
| Adrian G. Mann | M | - |
University of London
| 5 years |
| Jacqueline Le Saux | F | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 2 years |
| John Marshall | M | - |
University of London
| 7 years |
| Stanley S. Davis | M | - |
University of London
| 3 years |
| Michael Stephen Johnson | M | 74 |
University of London
| 5 years |
| Gerald Harper | M | 79 |
University of London
| 8 years |
| Alexander Metcalf | M | - |
University of London
| 10 years |
| Ruzairi bin Abdul Rahim | M | 58 |
Sheffield Hallam University
| 8 years |
| Nicolaus Eko Riwayanto | M | 65 |
Sheffield Hallam University
| 5 years |
| Geoffrey Thomas Tucker | M | - |
University of London
| 3 years |
| James Tak Him Lee | M | 76 |
University of London
| 4 years |
| Goodie Minabo Ibru | M | 82 |
University of London
| 3 years |
| Ajay Sharma | M | - |
University of London
| 3 years |
| Fouad Costandi Mitri Bajjali | M | 81 |
University of London
| 4 years |
| Ronald Eric Long | M | 77 |
The University of Reading
| 4 years |
| Hong Kok Cheng | M | 81 |
University of London
| - |
| Jane Louise Wilkinson | F | 54 |
Sheffield Hallam University
| 4 years |
| Somchai Kongsala | M | 85 |
University of London
| 3 years |
| Michael Askew | M | 74 |
University of London
| 4 years |
| Lik Gan Poh | M | 78 |
The University of Reading
| 4 years |
| Aloysius Kow | M | 78 |
University of London
| 4 years |
| Oghenakpobo Jonathan A. Idudu | M | - |
University of London
| 4 years |
| Bryan John Dyer | M | - |
The University of Reading
| 4 years |
| Ahmad Ibrahim Khalil Mango | M | 80 |
University of London
| 4 years |
| John Keenan | M | - |
University of London
| 4 years |
| Farhan Naser Abu Leil Abu Leil | M | - |
University of London
| - |
| Hilary A. Rodrigues | M | 81 |
University of London
| 3 years |
| Jo Davies | F | - |
Sheffield Hallam University
| 4 years |
| Aishah Ong | M | 79 |
University of London
| 4 years |
| Masleena binti Zaid | F | 49 |
Sheffield Hallam University
| 3 years |
| Chup Chau Kwok | M | 56 |
Sheffield Hallam University
| 4 years |
| Louise Batchelor | F | - |
Sheffield Hallam University
| 4 years |
| Cheng Yuen Foong | M | 78 |
University of London
| 3 years |
| Klaus Mueller | M | 54 |
Sheffield Hallam University
| 4 years |
| James Black | M | - |
University of London
| 4 years |
| Rosalind Nashashibi | F | 51 |
Sheffield Hallam University
| 4 years |
| Robert Maurice Lipson Winston | M | 83 |
University of London
| - |
| Glyn Ford | M | 74 |
The University of Reading
| 4 years |
| Richard Hawes | M | - |
University of London
| 4 years |
| Amal Mahmoud Shukri | F | 84 |
University of London
| - |
| Ross Henderson Paul | M | - |
University of London
| 1 years |
| Lizbeth Anne Littlewood | F | - |
Sheffield Hallam University
| 4 years |
| Robert King Park | M | 80 |
The University of Reading
| 3 years |
| Liming Wang | M | - |
Sheffield Hallam University
| 2 years |
| Hussameddin Taher Mohammed Al-Hodhod | M | 86 |
University of London
| - |
| Yeh Kwong Lee | M | 88 |
University of London
| 3 years |
| Anthony Gordon | M | - |
Sheffield Hallam University
| 4 years |
| James Salmon | M | - |
Sheffield Hallam University
| 4 years |
| Hazurin bin Harun | M | 54 |
Sheffield Hallam University
| 4 years |
| Paul Miller | M | - |
Sheffield Hallam University
| 1 years |
| Harvey M. J. Lawson | M | 75 |
University of London
| 4 years |
| Robert B. Royds | M | 79 |
University of London
| 3 years |
| William A. Cochrane | M | 98 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 3 years |
| Yos Euarchukiati | M | 81 |
University of London
| - |
| Derek Hall | M | - |
University of London
| 3 years |
| Charles Richard Vos | M | 79 |
University of London
| 4 years |
| Robert G. Horn | M | - |
University of London
| 1 years |
| Timothy Clark | M | - |
University of London
| 4 years |
| Hon Chuen Lau | M | 75 |
University of London
| 3 years |
| Anthony J. Payne | M | - |
University of London
| 3 years |
| Stephen E. Haggerty | M | - |
University of London
| 3 years |
| Julian Michael Horn-Smith | M | 76 |
University of London
| 4 years |
| Jonathan Fowler | M | - |
University of London
| 4 years |
| Bruce Seton | M | - |
University of London
| 3 years |
| Bernard Lim | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 6 years |
| André Bérard | M | 83 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 6 years |
| Eva Lee Kwok | F | 82 |
University of London
| 1 years |
| Nader Hamad Al-Sultan | M | 75 |
University of London
| 4 years |
| Surya Mohapatra | M | 74 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 4 years |
| Bruce R. Lederman | M | 80 |
University of London
| 1 years |
| Roger Thomas | M | 79 |
University of London
| 4 years |
| Leslie Hudson | M | 76 |
University of London
| 4 years |
| Paul van Damme | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 2 years |
| Alan Collett | M | 72 |
The University of Reading
| 4 years |
| Richard Ewing | M | - |
Sheffield Hallam University
| 1 years |
| John May | M | 76 |
University of London
| 4 years |
| Dacre Purchase | M | - |
Sheffield Hallam University
| 4 years |
| Su Yin Teoh | F | 53 |
Sheffield Hallam University
| 4 years |
| Floyd E. Toole | M | 87 |
University of London
| 3 years |
| Graham Turner | M | - |
University of London
| 4 years |
| Michael Charles Nott | M | 76 |
University of London
| 4 years |
| Charles Brooke | M | 82 |
University of London
| 4 years |
| Tak Ching Foo | M | 90 |
University of London
| 3 years |
| Christopher Wade Sherwell | M | 76 |
University of London
| 4 years |
| Antonio Melicio de Quadros | M | 82 |
University of London
| - |
| Anthony William Howland-Rose | M | 84 |
University of London
| 1 years |
| John Ho | M | 78 |
University of London
| 3 years |
| Chung Kwong Poon | M | 84 |
University of London
| 3 years |
| Mohamed Arif bin Nun | M | 78 |
University of London
| 4 years |
| Christopher W. J. Boatman | M | - |
University of London
| 4 years |
| Fouad Abdul Wahab Al-Bahrawi | M | 79 |
University of London
| 4 years |
| Simon J. Davis | M | 59 |
Sheffield Hallam University
| 4 years |
| Clive F. Burrett | M | 75 |
University of London
| 4 years |
| Martin Kavanagh | M | - |
University of London
| 4 years |
| Kris Taenar Wiluan | M | 76 |
University of London
| 4 years |
| David V. Jones | M | - |
The University of Reading
| 2 years |
| Steven William Ross | M | 52 |
Sheffield Hallam University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 92 | 92.00% |
| Canada | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anthony E. Bolton
- Personal Network
